STANDARD BIOTOOLS director granted RSUs and options

STANDARD BIOTOOLS INC. director Troy Cox reported equity awards consisting of restricted stock units and stock options as part of his compensation.

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. director Troy Cox reported equity awards consisting of restricted stock units and stock options as part of his compensation. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027, or one day before the company’s next annual stockholder meeting, subject to continued service. He also received stock options covering 175,923 shares of common stock at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 475,702 shares of common stock.

Insider Trade Summary

Grant/Award: 275,039 shares

Grant/Award 2 txns

Insider Cox Troy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	175,923	$0.00	$0.00
Grant/Award	Common Stock	99,116	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 175,923 contracts (Direct); Common Stock — 475,702 shares (Direct)

Footnotes (2)

1. F1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
2. F2. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

RSUs granted: 99,116 units Options granted: 175,923 shares Option exercise price: $0.8297 per share +3 more

6 metrics

RSUs granted 99,116 units Restricted Stock Units vesting by June 18, 2027 or before next annual meeting

Options granted 175,923 shares Stock options on common stock granted June 18, 2026

Option exercise price $0.8297 per share Exercise price for 175,923 stock options

Shares held after award 475,702 shares Common stock directly owned after RSU grant

Option expiration June 18, 2036 Expiration date of granted stock options

Option vesting start July 18, 2026 First vesting date, 12 equal monthly installments

Key Terms

Restricted Stock Units ("RSUs"), Stock Option (Right to buy), exercise price, vesting, +1 more

5 terms

Restricted Stock Units ("RSUs") financial

"Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to buy) financial

"Stock Option (Right to buy) with an exercise price of 0.8297 per share..."

exercise price financial

"conversion_or_exercise_price: "0.8297" for the stock option grant..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"RSUs vest in full on the earlier of June 18, 2027 and one day prior to the date of the Company's next annual meeting..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"The Option becomes exercisable in installments and has an expiration date of 2036-06-18..."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Troy Cox report in this Form 4 for STANDARD BIOTOOLS (LAB)?

Troy Cox reported equity awards, not open-market trades. He received 99,116 restricted stock units and stock options for 175,923 shares, all tied to continued board service, as part of his director compensation package.

How many restricted stock units did Troy Cox receive from STANDARD BIOTOOLS (LAB)?

Troy Cox received 99,116 restricted stock units. These RSUs vest in full on the earlier of June 18, 2027, or one day before the next annual stockholder meeting, assuming he continues serving with the company through that vesting date.

What are the terms of Troy Cox’s new stock options at STANDARD BIOTOOLS (LAB)?

He received stock options for 175,923 shares of common stock at a $0.8297 exercise price. The options vest in twelve equal monthly installments starting July 18, 2026, and expire on June 18, 2036, subject to his continued service.

Did Troy Cox buy or sell STANDARD BIOTOOLS (LAB) shares on the market?

No market purchases or sales were reported. The Form 4 shows award-type acquisitions of RSUs and stock options granted as compensation, not open-market buying or selling of STANDARD BIOTOOLS common stock.

How many STANDARD BIOTOOLS (LAB) shares does Troy Cox hold after these awards?

After the reported RSU grant, Troy Cox directly holds 475,702 shares of STANDARD BIOTOOLS common stock. This figure reflects his direct ownership position following the June 18, 2026 equity awards disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 05:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cox Troy

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		A		99,116(1)	A	$0	475,702	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.8297	06/18/2026		A		175,923		(2)	06/18/2036	Common Stock	175,923	$0	175,923	D

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 18, 2027 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

2. The Option becomes exercisable in twelve equal monthly installments beginning on July 18, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Troy Cox by Tomone Tanaka, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)